Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 43.13% is 31% above its 3-year average of 32.80%, near the high end of its 3-year range (-287.84%–50.14%).
5.16% below its 12-month average of 45.48%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 50.14%.
EBITDA MARGIN
43.13%
EBITDA MARGIN AVG TTM
45.48%
EBITDA MARGIN AVG 3Y
32.80%
EBITDA MARGIN AVG 5Y
32.80%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.16%
CURRENT VS 3Y AVG
+31.49%
CURRENT VS 5Y AVG
+31.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Krystal Biotech, Inc.
Market Cap
$9.54B
EBITDA Margin
43.13%
TTM Avg
45.48%
3Y Avg
32.80%
5Y Avg
32.80%
Market Cap
$9.12B
EBITDA Margin
13.28%
TTM Avg
13.13%
3Y Avg
16.37%
5Y Avg
17.13%
Market Cap
$9.96B
EBITDA Margin
18.42%
TTM Avg
17.41%
3Y Avg
19.12%
5Y Avg
20.05%
Market Cap
$10.06B
EBITDA Margin
2.15%
TTM Avg
3.41%
3Y Avg
4.20%
5Y Avg
4.49%
Market Cap
$10.07B
EBITDA Margin
10.47%
TTM Avg
10.43%
3Y Avg
10.38%
5Y Avg
10.85%
Market Cap
$8.90B
EBITDA Margin
-25.09%
TTM Avg
-47.89%
3Y Avg
-132.36%
5Y Avg
-132.36%
Market Cap
$10.23B
EBITDA Margin
19.75%
TTM Avg
19.29%
3Y Avg
19.87%
5Y Avg
21.06%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | $9.54B | 43.13% | 45.48% | 32.80% | 32.80% |
| Insulet Corp. (PODD)vs › | $9.38B | 21.67% | 20.24% | 16.36% | 15.66% |
| Henry Schein, Inc. (HSIC)vs › | $9.72B | 8.11% | 8.11% | 8.28% | 8.19% |
| Bruker Corporation (BRKR)vs › | $9.12B | 13.28% | 13.13% | 16.37% | 17.13% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.96B | 18.42% | 17.41% | 19.12% | 20.05% |
| Molina Healthcare, Inc. (MOH)vs › | $10.06B | 2.15% | 3.41% | 4.20% | 4.49% |
| The Ensign Group, Inc. (ENSG)vs › | $10.07B | 10.47% | 10.43% | 10.38% | 10.85% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.90B | -25.09% | -47.89% | -132.36% | -132.36% |
| Align Technology, Inc. (ALGN)vs › | $10.23B | 19.75% | 19.29% | 19.87% | 21.06% |
| Globus Medical, Inc. (GMED)vs › | $10.25B | 20.41% | 18.54% | 20.94% | 21.85% |
Gross Margin
93.3%
EBITDA Margin
43.1%
Operating Margin
44.9%
Net Margin
54.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 50.14% |
| 2026-03-31 | 47.62% |
| 2025-12-31 | 43.14% |
| 2025-09-30 | 43.95% |
| 2025-06-30 | 42.53% |
| 2025-03-31 | 42.88% |
| 2024-12-31 | 47.11% |
| 2024-09-30 | 28.58% |
| 2024-06-30 | 15.06% |
| 2024-03-31 | -11.22% |
| 2023-12-31 | 11.02% |
| 2023-09-30 | -287.84% |
| 2019-06-30 | -1054.43% |
| 2019-03-31 | -782.50% |
| 2018-12-31 | -404.87% |
| 2018-09-30 | -1352.07% |
| 2018-06-30 | -1401.73% |
| 2018-03-31 | -1778.74% |
